Related references
Note: Only part of the references are listed.Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
Aimee R. Kreimer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention A pooled analysis of 11 clinical trials
Dominique Descamps et al.
HUMAN VACCINES (2009)
Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2009)
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
B. Romanowski et al.
LANCET (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine
Francis J. Dessy et al.
HUMAN VACCINES (2008)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen et al.
LANCET (2007)
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like pailicle vaccine containing AS04 adjuvant
Court Pedersen et al.
JOURNAL OF ADOLESCENT HEALTH (2007)
Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
DM Harper et al.
LANCET (2006)
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
DM Harper et al.
LANCET (2004)
A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: Antibody responses, safety, and immunologic memory
WM Cassidy et al.
PEDIATRICS (2001)
Share Paper
